Literature DB >> 13679638

Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer.

Motomu Shimizu1, Takayuki Yoshimoto, Akio Matsuzawa, Yasutaka Takeda.   

Abstract

Electroporation is a method for introducing DNA into cells by using a high-voltage electric field. This method is very simple and easily manipulated. We describe here a method for the modification of tumor cells with the Fas/Apo-1 (CD95) antigen-gene and Fas ligand (FasL)-gene transfection through the use of electroporation, and suggest that the Fas-FasL system is a good target for the induction of apoptosis-mediated antitumor activity. The Fas receptor/ligand system induces apoptosis and plays an important role in regulation of the immune system. In the method described, hepatoma MH134 (Fas- and FasL-) is transfected with murine Fas and FasL cDNA. A single administration of monoclonal anti-Fas antibody efficiently suppresses the growth of F6b (MH134+Neo+Fas) tumors but not that of N1d (MH134+Neo) tumors in gld/gld lpr/lpr mice. MH134+Neo+FasL tumor cells were rejected after the induction of inflammation with infiltration of neutrophils in mice. These results suggest that electroporation and Fas-mediated apoptosis are a good method for inducing of antitumor activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679638     DOI: 10.1385/MB:25:1:79

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  14 in total

1.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Authors:  T Suda; T Takahashi; P Golstein; S Nagata
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

Review 2.  Fas-ligand: privilege and peril.

Authors:  D R Green; C F Ware
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

3.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

4.  A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo.

Authors:  M Shimizu; T Yoshimoto; S Nagata; A Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1996-11-12       Impact factor: 3.575

5.  Monoclonal antibody-mediated tumor regression by induction of apoptosis.

Authors:  B C Trauth; C Klas; A M Peters; S Matzku; P Möller; W Falk; K M Debatin; P H Krammer
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

6.  Lethal effect of the anti-Fas antibody in mice.

Authors:  J Ogasawara; R Watanabe-Fukunaga; M Adachi; A Matsuzawa; T Kasugai; Y Kitamura; N Itoh; T Suda; S Nagata
Journal:  Nature       Date:  1993-08-26       Impact factor: 49.962

7.  Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation.

Authors:  H Potter; L Weir; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

8.  Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells.

Authors:  M Shimizu; Y Takeda; H Yagita; T Yoshimoto; A Matsuzawa
Journal:  Cancer Immunol Immunother       Date:  1998-11       Impact factor: 6.968

Review 9.  Fas and Fas ligand: lpr and gld mutations.

Authors:  S Nagata; T Suda
Journal:  Immunol Today       Date:  1995-01

10.  Gene transfer into mouse lyoma cells by electroporation in high electric fields.

Authors:  E Neumann; M Schaefer-Ridder; Y Wang; P H Hofschneider
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.